Showing 1981-1990 of 3223 results for "".
- Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.https://modernod.com/news/alcon-launches-systane-hydration-multi-dose-preservative-free-lubricant-eye-drops-in-the-u-s/2479131/Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of the newest addition to its innovative portfolio of dry eye products – Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Dro
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2021-arvo-annual-meeting/2479123/Allegro Ophthalmics announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held virtually May 1-7, 2021. “It’s e
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis/2479122/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for the primary endpo
- Allergan to Share New Data Highlighting Latest Advancements in Eye Care at ARVO 2021https://modernod.com/news/allergan-to-share-new-data-highlighting-latest-advancements-in-eye-care-at-arvo-2021/2479116/Allergan announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting (May
- Johnson & Johnson Vision Receives Approval in Canada for First Drug-Releasing Contact Lens for Vision Correction and Allergic Eye Itchhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-first-drug-releasing-contact-lens-for-vision-correction-and-allergic-eye-itch/2479117/Johnson & Johnson Vision received Health Canada approval for the first and only daily disposable contact lens for vision correction in patients who experience itchy allergy eyes due to allergic conjunctivitis: Acuvue Theravision with Ketotifen.1 The lens contains an H1 hista
- US Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucomahttps://modernod.com/news/us-patent-office-issues-notice-of-allowance-for-nicoxs-latanoprostene-bunod-in-normal-tension-glaucoma/2479119/Nicoy announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as Vyzulta for
- Hillrom Launches Welch Allyn PanOptic Plus Ophthalmoscopehttps://modernod.com/news/hillrom-launches-digital-physical-assessment-innovations-to-advance-connected-care/2479106/Hillrom announced technological advances to its physical assessment tools with the launch of the new Welch Allyn PanOptic Plus Ophthalmoscope and the Welch Allyn MacroView Plus Otoscope. Examining the structure of the eyes and ears is a critical part of assessing p
- US Patents for Nicox’s Vyzulta (Latanoprostene Bunod) Eligible for Patent Term Extensionhttps://modernod.com/news/us-patents-for-nicoxs-vyzulta-latanoprostene-bunod-eligible-for-patent-term-extension/2479103/Nicox SA announced that the United States Patent and Trademark Office (USPTO) has determined that three U.S. composition of matter patents covering latanoprostene bunod, commercialized as Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, are eligible for patent term extension, potential
- Alcon Canada Introduces UV Only IOLs for AcrySof IQ PanOptix and AcrySof IQ Vivity Portfolioshttps://modernod.com/news/alcon-canada-introduces-uv-only-iols-for-acrysof-iq-panoptix-and-acrysof-iq-vivity-portfolios/2479066/Alcon has announced the availability of AcrySof IQ PanOptix UV IOL, AcrySof IQ PanOptix Toric UV IOL, AcrySof IQ Vivity UV IOL, and AcrySof IQ Vivity Toric UV IOL as part of the presbyopia-correcting lens portfolio in Canada.1 These next-generation IOLs
- Allergan Launches New Consumer Ad Campaign for Restasishttps://modernod.com/news/allergan-launches-new-consumer-ad-campaign-for-restasis/2479065/Allergan announced it is launching a direct-to-consumer (DTC) broadcast TV advertising campaign for Restasis (cyclosporine ophthalmic emulsion) 0.05%, launching April 2021. Restasis has been FDA approved for 17 years and is the #1 dispensed branded eye drop, prescribed